No products in the cart.
Cagrilintide (5mg)
$60.00
Cagrilintide is a long-acting amylin analogue designed for once-weekly subcutaneous administration, developed to complement GLP-1 receptor agonists for superior weight management. By mimicking the action of amylin, a hormone released alongside insulin, Cagrilintide slows gastric emptying, reduces glucagon secretion, and promotes satiety through central nervous system pathways. It is frequently combined with semaglutide (as in the CagriSema combination) to produce additive weight loss effects, making it a highly anticipated tool in metabolic medicine and body recomposition.
Every order of Forza peptides includes one (1) bottle of Bacteriostatic Water (10mL).
Purchase this and earn 60 Forza Reward Points valued at $3.00Description
Dosage (Male)
0.16-2.4mg per week (titrated gradually)
Dosage (Female)
0.16-1.7mg per week (titrated gradually)
Dosage Frequency
Once weekly
Dosage Type
Subcutaneous injection
The Amylin Advantage in Weight Management
Cagrilintide works through a distinct and complementary mechanism to GLP-1 receptor agonists by mimicking amylin, a hormone co-secreted with insulin that helps regulate post-meal glucose levels and satiety. This unique pathway slows gastric emptying, reduces post-meal glucagon spikes, and signals fullness through central amylin receptors, creating powerful and sustained appetite suppression. When combined with semaglutide or tirzepatide, Cagrilintide has demonstrated additive weight loss effects far exceeding either compound alone. For physique athletes and those targeting aggressive fat loss, this combination represents one of the most exciting frontiers in metabolic optimization.
A Game-Changer in Combination Protocols
Clinical research on CagriSema (Cagrilintide + Semaglutide) has shown weight loss results approaching surgical levels, with participants losing an average of over 15% of body weight in trials. For bodybuilders and fitness athletes, Cagrilintide once-weekly dosing schedule makes it extremely practical to incorporate into existing peptide protocols. Its complementary mechanism to GLP-1 agonists means users experience enhanced appetite control, better glycemic stability, and accelerated fat loss without significant increases in side effects. When used responsibly as part of a comprehensive recomposition strategy, Cagrilintide can be the missing piece that takes results to an entirely new level.
Side Effects & Considerations
Cagrilintide is generally well tolerated, with a side effect profile similar to other amylin analogues and GLP-1 receptor agonists. Common side effects include nausea, vomiting, diarrhea, decreased appetite, and injection site reactions. Mild hypoglycemia may occur, particularly when combined with other glucose-lowering agents. Less common effects include headache, fatigue, and dizziness. Cagrilintide is not recommended for individuals with severe gastrointestinal conditions or a history of hypersensitivity to amylin analogues. Pregnant or breastfeeding individuals should consult a physician before use. As with all injectable peptides, rotate injection sites and use proper sterile technique.
Reviews
There are no reviews yet.